TrianglePUBLICATIONS · 37506346
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2023 Nov 20
- First author
- Zinzani PL
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Zinzani PL
- type
- Author
- name
- Mayer J
- type
- Author
- name
- Flowers CR
- type
- Author
- name
- Bijou F
- type
- Author
- name
- De Oliveira AC
- type
- Author
- name
- Song Y
- type
- Author
- name
- Zhang Q
- type
- Author
- name
- Merli M
- type
- Author
- name
- Bouabdallah K
- type
- Author
- name
- Ganly P
- type
- Author
- name
- Zhang H
- type
- Author
- name
- Johnson R
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Zinzani PL
- type
- Author
- name
- Mayer J
- type
- Author
- name
- Flowers CR
- type
- Author
- name
- Bijou F
- type
- Author
- name
- De Oliveira AC
- type
- Author
- name
- Song Y
- type
- Author
- name
- Zhang Q
- type
- Author
- name
- Merli M
- type
- Author
- name
- Bouabdallah K
- type
- Author
- name
- Ganly P
- type
- Author
- name
- Zhang H
- type
- Author
- name
- Johnson R
- type
- Author
- bibliography ids
- nci-bib-b09ff3102518db5f1e2abf57
- book metadata
- content sha256
- 48de41aa771e88adce59ae55d8bef3d1df1e136e402728459f5b0aafa9ade28f
- document type
- citation
- dois
- 10.1200/JCO.23.00775
- electronic publication date
- display
- 2023 Jul 28
- precision
- day
- year
- 2023
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:37506346
- immutable id
- pubmed:37506346@48de41aa771e88adce59ae55d8bef3d1df1e136e402728459f5b0aafa9ade28f
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 33
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 5107-5117
- volume
- 41
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 37506346
- provenance
- batch id
- 5329a5d0877ee70ecd11
- provider
- NCBI PubMed ESummary
- record sha256
- 41697ead5fb41ad0149b131138d3be3545ce6ca4f30ae8ffc3069e7a56e4cc8f
- response sha256
- bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
- retrieved at
- 2026-09-09T23:48:15.763286+00:00
- publication date
- display
- 2023 Nov 20
- precision
- day
- year
- 2023
- publication types
- Clinical Trial, Phase II
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Preserved source evidence · Independent clinical review pending · Not medical advice